NeuroSense Therapeutics (NRSNW) Projected to Post Quarterly Earnings on Wednesday

NeuroSense Therapeutics (NASDAQ:NRSNW) is expected to be announcing its resultson Wednesday, March 25th. Analysts expect the company to announce earnings of ($0.1050) per share for the quarter.

NeuroSense Therapeutics Stock Down 15.9%

NASDAQ:NRSNW opened at $0.18 on Wednesday. NeuroSense Therapeutics has a 1 year low of $0.16 and a 1 year high of $1.00. The business has a 50 day simple moving average of $0.25 and a 200-day simple moving average of $0.33.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.